Market Overview

The Red Biotechnology Market is expected to register a CAGR of 5.7% during the forecast period. Red biotechnology is a process that utilizes organisms to improve health and helps the body to fight against diseases. Red biotechnology has become a very important part of the field of diagnostics, gene therapy, and clinical research and trials. Genetic engineering and the development and production of various new medicinal products to treat life-threatening diseases are also part of the benefits of red biotechnology. Severe Combined Immune Deficiency (SCID) and Adenosine deaminase (ADA) deficiency are genetic disorders that were successfully treated with gene therapy. Several promising gene therapies are under development for the treatment of cancer and genetic disorders. According to the World Health Organization (WHO), approximately 6,000 to 8,000 rare diseases found and out of them, nearly 80% are genetic disorders. Rising incidence and prevalence of chronic and rare diseases and increased funding in the healthcare industry are the key driving factors in the red biotechnology market.

Scope of the Report

Red biotechnology is a process that utilizes organisms to improve health and helps the body to fight against diseases. Red biotechnology Market is segmented by Market Participant and Geography.

Key Market Trends

Biopharmaceutical Industry Segment is Expected to Hold a Major Market Share in the Red biotechnology Market

  • Biopharmaceuticals are medical drugs that are produced by using biotechnology. Biopharmaceuticals are proteins, antibodies, DNA, RNA or antisense oligonucleotides used for therapeutic or diagnostic purposes, and these products are produced by means other than direct extraction from a native (non-engineered) biological source.
  • The first biopharmaceutical product approved for therapeutic use was recombinant human insulin (Humulin), which was developed by Genentech and marketed by Eli Lily in the year 1982 and in the year 2019, Novartis received FDA approval for gene therapy product in the treatment of spinal muscular atrophy (SMA) condition. Using an AAV9 viral vector, called Zolgensma, which delivers SMN protein into the motor neurons of afflicted patients.
  • According to the World Health Organization (WHO), globally Cancer is the second leading cause of death and an estimated 9.6 million deaths in the year 2018.
  • Increasing incidence and prevalence of chronic and rare diseases and rapid expansion of the biopharmaceutical industries are the key driving factors in the biopharmaceutical industry segment.



North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America expected to hold a major market share in the global red biotechnology market due to the rising prevalence of chronic and rare diseases, increased expenditure in the healthcare industry in this region. According to the National Institutes of Health (NIH), in the year 2019, approximately 1.8 million people will be diagnosed with cancer in the United States and estimated 268,600 women and 2,670 men will be diagnosed with breast cancer. Moreover, the rise in the adoption of advanced technologies in gene therapy and increasing investments in research and development is fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Red Biotechnology Market is consolidated competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some prominent players are vigorously making acquisitions with the other companies to consolidate their market positions across the globe. Some of the companies which are currently dominating the market are Pfizer Inc, AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Celgene Corporation, Takeda Pharmaceutical Company Limited, Biogen Inc, Amgen Inc, Gilead Sciences Inc, Merck KGaA, CSL Limited.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client’s requirements
  • 3 months of analyst support